Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxford BioMedica PLC

www.oxfordbiomedica.co.uk

Latest From Oxford BioMedica PLC

Interview: Orchard's Gene Therapies Bear Fruit With $110m Financing

The UK firm has attracted more top-tier investors who are clearly impressed with its gene therapy for bubble baby syndrome and a high-quality pipeline in other very rare diseases.

Rare Diseases Financing

Sanofi-Backed Voyager Therapeutics Hails Gene Therapy's Arrival

Emerging Company Profile: With a pipeline of products for neurological diseases and a collaboration with Sanofi's Genzyme, Voyager Therapeutics is confident that its 'one-shot' gene therapy could be the answer to treating serious diseases of the brain. CEO Steven Paul shares development and funding plans and hopes to make Voyager's gene therapies the answer to neurological maladies.

BioPharmaceutical Companies

2Q Pharma Results Preview: Novartis And J&J Lead The Pack

Scrip offers some top topics to monitor as second-quarter biopharmaceutical sales and earnings start to be unveiled. First out of the blocks will be Johnson & Johnson and Novartis AG. Recent and coming launches, pricing strategies, M&A and the biosimilar landscape are key themes to watch out for as the duo and other players update at their half-year points.

Commercial Sales & Earnings

Novartis CAR-T Site Selection, Risk Management Are Model For Other Sponsors

US advisory committee's favorable views of Novartis' tisagenlecleucel-T suggest road map for other CAR-T developers to follow; with an Oct. 3 user fee deadline, pediatric leukemia agent is on path to becoming first chimeric antigen receptor T-cell therapy in US.

Advisory Committees Drug Review
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
  • Services
  • Therapeutic Areas
  • Cancer
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Oxford BioMedica PLC
  • Senior Management
  • John Dawson, CEO
    Tim Watts, CFO
    Peter Nolan, Chief Business Officer
    Paul Blake, MD, CDO
    Kyriacos Mitrophanous, CSO
    James Miskin, CTO
  • Contact Info
  • Oxford BioMedica PLC
    Phone: (44) 1865 783 000
    Medawar Ctr., Robert Robinson Ave.
    Oxford Sci. Pk
    Oxford, OX4 4GA
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register